Get the Stockscreener App
0.161
21.52%
-0.049
After Hours:
.16
-0.001
-0.62%
Bio Path Holdings Inc stock is traded at $0.161, with a volume of 783.
It is down -21.52% in the last 24 hours and down -80.61% over the past month.
See More
Previous Close:
$0.21
Open:
$0.171
24h Volume:
783
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-16.08M
P/E Ratio:
-0.00468
EPS:
-34.43
Net Cash Flow:
$-11.54M
1W Performance:
-21.52%
1M Performance:
-80.61%
6M Performance:
-86.27%
1Y Performance:
-97.18%
1-Day Range:
$0.161
$0.171
1-Week Range:
$0.161
$0.171
52-Week Range:
$0.161
$0.171
Bio Path Holdings Inc Stock (BPTH) Company Profile
Compare BPTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.161 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-21 | Initiated | ROTH Capital | Buy |
| Nov-13-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Apr-18-16 | Initiated | Rodman & Renshaw | Buy |
| Jun-02-14 | Resumed | Maxim Group | Buy |
| May-09-14 | Initiated | Maxim Group | Buy |
View All
Bio Path Holdings Inc Stock (BPTH) Latest News
Transcript : Bio-Path Holdings, Inc.Special Call - marketscreener.com
Crown LNG Holdings Limited Discloses Receipt of NASDAQ Notice - The Manila Times
Bio-Path Holdings to Host Corporate Update Conference Call on Ma - GuruFocus
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 | BPTH Stock News - GuruFocus
Bio-Path Holdings, Inc. to Host Live Conference Call on May 29, 2025, for Business Overview - Nasdaq
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 - The Manila Times
Bio-Path Holdings to Reveal Latest Progress on Cancer Drug Pipeline and New Obesity Treatment Program - Stock Titan
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Procure Space ETF (UFO) Adds Unidentified Aerial Phenomena Risk Disclosure to Prospectus - The Globe and Mail
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
Bio-Path: Q1 Earnings Snapshot - CT Insider
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid - The Globe and Mail
Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com - Defense World
Bio-Path (BPTH) to Release Earnings on Wednesday - Defense World
PTC hits Huntington biomarker, but approval path still uncertain - BioCentury
Small Interfering RNA (siRNA) Therapeutics Market Know the Scope and Trends - openPR.com
StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH) - Defense World
This More Than 5%-Yielding Dividend Stock Looks Like a Can't-Miss Buy for Income and Upside Potential - The Globe and Mail
Global Chronic Myeloid Leukemia (CML) Treatment Market To Expand At A CAGR Of 7% Reaching $$11.39 Billion B... - WhaTech
Bio-Path (BPTH): Promising Preclinical Results for Obesity Treat - GuruFocus
Bio-Path (BPTH): Promising Preclinical Results for Obesity Treatment | BPTH Stock News - GuruFocus
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - The Manila Times
Microbix Presenting at the 2025 Bloom Burton Conference - The Manila Times
Acute Myeloid Leukemia Drugs Market 2034: EMA, PDMA, FDA - openPR.com
Bio-Path Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Cutaneous T-Cell Lymphoma Clinical Trials and Studies 2025: - openPR.com
Cutaneous T-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Longleaf Partners Fund Believes PayPal Holdings (PYPL) Has a Compelling Path Forward - Yahoo Finance
StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH) - Defense World
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
Indo-Asian News Service - Indo-Asian News Service (IANS)
Acute Myeloid Leukemia Treatment Market 2034: Clinical Trials, - openPR.com
Small Interfering RNA (siRNA) Therapeutics Market Revenue Report with Forecast to 2031 - openPR.com
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World
What is Roth Capital’s Forecast for Bio-Path Q1 Earnings? - Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q2 2024 Earnings Call Transcript - MSN
Bio-Path Holdings Reports 2024 Financial Results and Progress - TipRanks
Bio-Path Holdings Reports Full Year 2024 Financial Results - MarketScreener
Bio-Path Slashes Annual Losses While Breakthrough Obesity Treatment Shows Promise - Stock Titan
Cutaneous T-Cell Lymphoma (CTCL) Treatment Market 2034: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - Barchart
North American Morning Briefing : Tariff Jitters -2- - Marketscreener.com
Small Interfering RNA (siRNA) Therapeutics Market Forecast to Expand with Growing Investment in RNA Therape... - WhaTech
Bio Path Holdings Inc Stock (BPTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Cap:
|
Volume (24h):